Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00924092 | An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ... | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 |
| clinicaltrials |
| NCT02946008 | Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer | completed | Phase 1 | 17 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT00214097 | Phase I/II Hypofractionated Radiotherapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 347 | University of Wisconsin, MadisonOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00702923 | CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer | terminated | Phase 1 | 12 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00582140 | Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer | completed | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00002677 | Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors | completed | Phase 1 | 24 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT04148885 | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 44 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT00456989 | Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 39 | University of LouisvilleOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02423928 | Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer(CryoIT) | completed | Phase 1 | 18 | Alden Cancer Therapy IIINDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02500901 | Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | terminated | Phase 1 | 2 | Paul Mathew, MDOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT00868595 | MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer | completed | Phase 1 | 18 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 8, 2019 | clinicaltrials |
| NCT01146340 | Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer(PHART6) | completed | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT00510718 | A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer | completed | Phase 1 | 140 | PfizerINDUSTRY | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01585246 | Saw Palmetto: Symptom Management for Men During Radiation Therapy | completed | Phase 1 / Phase 2 | 48 | Michigan State UniversityOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT02274623 | Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid | completed | Phase 1 | 33 | OPKO Health, Inc.INDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT04107142 | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | unknown | Phase 1 | 10 | CytoMed Therapeutics Pte LtdINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT00124917 | Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer | terminated | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2019 | clinicaltrials |
| NCT02324998 | Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy(CaNCaP03) | completed | Phase 1 | 20 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Aug 29, 2019 | clinicaltrials |
| NCT02262910 | Study of ES414 in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 35 | Aptevo TherapeuticsINDUSTRY | 2 | Aug 28, 2019 | clinicaltrials |
| NCT01083368 | Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy | completed | Phase 1 / Phase 2 | 22 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT01084655 | Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01028885 | MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate | completed | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00669162 | Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Kansas Medical CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT02796898 | Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 23 | Tyme, IncINDUSTRY | 1 | Jul 22, 2019 | clinicaltrials |
| NCT02064608 | Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer(CaNCaP02) | completed | Phase 1 | 23 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT00636558 | Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)(PSX-X04) | completed | Phase 1 | 8 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT02182622 | LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | withdrawn | Phase 1 | 0 | Martin GutierrezOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01565928 | Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer | completed | Phase 1 | 23 | PfizerINDUSTRY | 1 | Apr 22, 2019 | clinicaltrials |
| NCT00348595 | Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer | completed | Phase 1 / Phase 2 | 77 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03030885 | Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | completed | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT00996502 | Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT02111187 | A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer(LDE225) | completed | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00311623 | Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT01094288 | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | completed | Phase 1 | 41 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02507427 | Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study) | completed | Phase 1 / Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02202447 | Phase 1 of EC1169 In Patients With Recurrent MCRPC | completed | Phase 1 | 40 | EndocyteINDUSTRY | 1 | Feb 7, 2019 | clinicaltrials |
| NCT01741753 | BKM120+Abiraterone Acetate for Metastatic CRPC | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02361086 | A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 21 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02478125 | Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01417182 | Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer | completed | Phase 1 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT00790374 | BN83495 in Prostate Cancer(STX64PC) | completed | Phase 1 | 17 | IpsenINDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT03450109 | A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer | completed | Phase 1 | 19 | Luye Pharma Group Ltd.INDUSTRY | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01262664 | A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02655952 | Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients | completed | Phase 1 | 17 | WntResearch ABINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
| NCT00924807 | Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Medical CenterOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00059631 | Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | completed | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 12, 2019source: clinicaltrials